Grifols, one of world’s top producers of plasma-derived medicines, has entered an agreement to acquire GC Pharma Group’s Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for $460 million. The transaction is part of Grifols’ global growth strategy to expand plasma collection and fractionation capacity to help ensure safe and secure access to life-saving plasma-derived medicines. This strategic acquisit...